SGAM
RVLP

Smith Group Asset Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Smith Group Asset Management’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-51,890
Closed -$214K – 346
2020
Q4 		$214K Sell
51,890
-130
-0.2% -$749 0.01% 177
2020
Q3 		$281K Buy
+52,020
New +$300K 0.01% 154

Other funds holding RVLP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's RVLP Position: Q1 2021 in Review

Smith Group Asset Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q1 2021, closing a stake of 51,890 shares — an estimated $214K sold.

Smith Group Asset Management first reported a position in RVLP in Q3 2020 and held it in 2 quarters. The position peaked at $281K in Q3 2020. 55 funds tracked by Wall St. Rank hold RVLP as of Q1 2021.

  • Smith Group Asset Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • Smith Group Asset Management sold 51,890 RVL Pharmaceuticals plc Ordinary Shares shares in Q1 2021, an estimated $214K.
  • Smith Group Asset Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2020 and held it in 2 quarters.
  • Smith Group Asset Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $281K in Q3 2020.
  • 55 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q1 2021.

Based on Smith Group Asset Management's 13F filing for Q1 2021, filed 7 May 2021.